Daniel Mølager Christensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Mølager Christensen has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Morten Schou
Department of Clinical Medicine, University of Copenhagen , Copenhagen
12 shared publications - Lars Køber
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
11 shared publications - Gunnar Hilmar Gislason
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte , Hospitalsvej 1, 2900 Hellerup
10 shared publications - Jarl Emanuel Strange
Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen
9 shared publications - Emil Loldrup Fosbøl
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, Copenhagen 2100
8 shared publications Gunnar Gislason
Danish Heart Foundation, Copenhagen, Denmark; Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; The National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
8 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by Elsevier in American Heart Journal
- Vol. 303
Clinical outcomes associated with recurrent compared to first-time myocardial infarction
- 30 August 2026
- Published by Elsevier in American Heart Journal
- Vol. 303
Open AccessClinical outcomes associated with recurrent compared to first-time myocardial infarction
- Open Access
- 12 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Chronic but not Transient Anemia Is Associated With Atrial Fibrillation Recurrence After Catheter Ablation
Background: Anemia is common in patients with atrial fibrillation (AF). Prior studies have associated anemia—based on a single pre‐procedural hemoglobin measurement—with AF recurrence after catheter ablation. However, it remains unclear whether chronic anemia confers a different risk compared with transient anemia. This study evaluated the association between transient and chronic anemia and AF recurrence following first‐time catheter ablation. Methods: In this nationwide cohort study, we included 15 017 patients from the Danish National Ablation Database undergoing first‐time AF ablation between 2010 and 2024 with available hemoglobin measurements within 12 months prior to the procedure. Patients were categorized as having no anemia, transient anemia, or chronic anemia based on repeated hemoglobin measurements. The primary outcome was AF recurrence within 1 year after a 90‐day blanking period, defined as a composite of AF‐related hospitalization, cardioversion, antiarrhythmic drug use, or repeat ablation. Associations were assessed using multivariable Cox proportional hazards models. Results: A total of 877 patients (5.8%) had chronic anemia and 1592 (10.6%) had transient anemia. During follow‐up, 3445 patients (23.6%) experienced AF recurrence. The 1‐year cumulative incidence of recurrence was highest in patients with chronic anemia (32.5%), followed by transient anemia (24.2%) and no anemia (23.0%). Compared with non‐anemic patients, chronic anemia was independently associated with an increased risk of AF recurrence (adjusted hazard ratio [HR]: 1.36; 95% confidence interval [CI]: 1.18–1.56), whereas transient anemia was not (HR: 0.98; 95% CI: 0.87–1.10). Conclusion: Chronic—but not transient—anemia prior to first‐time catheter ablation was independently associated with a higher risk of AF recurrence.
- 12 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Open AccessChronic but not Transient Anemia Is Associated With Atrial Fibrillation Recurrence After Catheter Ablation
Background: Anemia is common in patients with atrial fibrillation (AF). Prior studies have associated anemia—based on a single pre‐procedural hemoglobin measurement—with AF recurrence after catheter ablation. However, it remains unclear whether chronic anemia confers a different risk compared with transient anemia. This study evaluated the association between transient and chronic anemia and AF recurrence following first‐time catheter ablation. Methods: In this nationwide cohort study, we included 15 017 patients from the Danish National Ablation Database undergoing first‐time AF ablation between 2010 and 2024 with available hemoglobin measurements within 12 months prior to the procedure. Patients were categorized as having no anemia, transient anemia, or chronic anemia based on repeated hemoglobin measurements. The primary outcome was AF recurrence within 1 year after a 90‐day blanking period, defined as a composite of AF‐related hospitalization, cardioversion, antiarrhythmic drug use, or repeat ablation. Associations were assessed using multivariable Cox proportional hazards models. Results: A total of 877 patients (5.8%) had chronic anemia and 1592 (10.6%) had transient anemia. During follow‐up, 3445 patients (23.6%) experienced AF recurrence. The 1‐year cumulative incidence of recurrence was highest in patients with chronic anemia (32.5%), followed by transient anemia (24.2%) and no anemia (23.0%). Compared with non‐anemic patients, chronic anemia was independently associated with an increased risk of AF recurrence (adjusted hazard ratio [HR]: 1.36; 95% confidence interval [CI]: 1.18–1.56), whereas transient anemia was not (HR: 0.98; 95% CI: 0.87–1.10). Conclusion: Chronic—but not transient—anemia prior to first‐time catheter ablation was independently associated with a higher risk of AF recurrence.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-8
Heart Failure Phenotypes Across Age Groups in the Danish Administrative Registers
Background: The Danish administrative registers are a powerful tool for heart failure (HF) research. However, the coding system has historically does not distinguished between HF phenotypes. We aimed to identify the distribution of HF with reduced ejection fraction (HFrEF), mildly reduced EF (HFmrEF), and preserved EF (HFpEF) within the Danish National Patient Register overall and across age groups. Methods: We manually reviewed electronic health records of all patients with an incident primary diagnosis of HF (ICD-10: I50) at two large university hospitals in the Capital Region of Denmark between June 2021 and May 2024. HFrEF was defined as left ventricular ejection fraction (LVEF) ≤ 40%, HFmrEF as 41– 49%, and HFpEF as ≥ 50%. Patients without available echocardiographic measurements were classified together with the HFpEF group. The phenotypic distribution was stratified by age groups (< 65, 65– 79, and ≥ 80 years) and six clinical subgroups (female sex, obesity, chronic kidney disease, atrial fibrillation/flutter, diabetes, and ischemic heart disease). Results: Following manual review of 1888 patients with a primary diagnosis of HF (median age 74, 67% male), 1687 (89%) had HFrEF, 72 (4%) HFmrEF, and 129 (7%) HFpEF. HFrEF was dominant across all ages but was lower with advancing age: 95% in patients aged < 65 years, 90% in those aged 65– 79, and 83% among those aged ≥ 80. In all clinical subgroups, the proportion of HFrEF remained high, ranging from 83 to 90%. Conclusion: Patients with an incident hospital diagnosis of HF at two Danish university hospitals predominantly presented with HFrEF. This phenotype distribution may reflect that of patients diagnosed with HF in the Danish National Patient Register. Even among those aged ≥ 80 years, fewer than one in five patients presented with HFmrEF or HFpEF. These findings provide a necessary reference for interpreting Danish registry-based HF data and inform the design of future registry-based clinical trials.
- 1 August 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-8
Open AccessHeart Failure Phenotypes Across Age Groups in the Danish Administrative Registers
Background: The Danish administrative registers are a powerful tool for heart failure (HF) research. However, the coding system has historically does not distinguished between HF phenotypes. We aimed to identify the distribution of HF with reduced ejection fraction (HFrEF), mildly reduced EF (HFmrEF), and preserved EF (HFpEF) within the Danish National Patient Register overall and across age groups. Methods: We manually reviewed electronic health records of all patients with an incident primary diagnosis of HF (ICD-10: I50) at two large university hospitals in the Capital Region of Denmark between June 2021 and May 2024. HFrEF was defined as left ventricular ejection fraction (LVEF) ≤ 40%, HFmrEF as 41– 49%, and HFpEF as ≥ 50%. Patients without available echocardiographic measurements were classified together with the HFpEF group. The phenotypic distribution was stratified by age groups (< 65, 65– 79, and ≥ 80 years) and six clinical subgroups (female sex, obesity, chronic kidney disease, atrial fibrillation/flutter, diabetes, and ischemic heart disease). Results: Following manual review of 1888 patients with a primary diagnosis of HF (median age 74, 67% male), 1687 (89%) had HFrEF, 72 (4%) HFmrEF, and 129 (7%) HFpEF. HFrEF was dominant across all ages but was lower with advancing age: 95% in patients aged < 65 years, 90% in those aged 65– 79, and 83% among those aged ≥ 80. In all clinical subgroups, the proportion of HFrEF remained high, ranging from 83 to 90%. Conclusion: Patients with an incident hospital diagnosis of HF at two Danish university hospitals predominantly presented with HFrEF. This phenotype distribution may reflect that of patients diagnosed with HF in the Danish National Patient Register. Even among those aged ≥ 80 years, fewer than one in five patients presented with HFmrEF or HFpEF. These findings provide a necessary reference for interpreting Danish registry-based HF data and inform the design of future registry-based clinical trials.
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e044072
Care and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022
Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e044072
Open AccessCare and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022
Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.
- 18 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (27) , 3625-3635
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.
- 18 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (27) , 3625-3635
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.
- Open Access
- 13 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study
- 13 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Open AccessCare and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study
- 1 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (12) , 723-731
Long-term outcomes of recurrent myocardial infarction: a nationwide Danish study
Aims: During the past decades outcomes of first-time myocardial infarction (MI) have improved substantially. However, it is unknown if the prognosis following a recurrent MI has also improved similarly. Methods and results: We conducted a nationwide registry-based study including all patients with first-time recurrent MI in Denmark during 2003 to 2022. Cumulative incidences and standardized risk ratios (sRR) of mortality, hospitalisation for heart failure (HHF), and subsequent recurrent MI were reported along with stratified analyses by age, sex, and HF status at baseline. A total of 24,799 patients with recurrent MI were identified. Between 2003 and 2007 (n = 7368) and 2018–2022 (n = 4928), their median age decreased from 75 to 73 years. The prevalence of non-cardiovascular comorbidities increased. The use of lipid-lowering treatment at baseline increased (53.7% to 76.6%), as well as procedures performed in relation to recurrent MI (coronary angiogram, 41.2% to 77.4%; percutaneous coronary intervention, 26.8% to 54.0%). 5-year mortality decreased from 54.1% to 37.3% [sRR: 0.78 (0.74–0.82)], 5-year incidence of HHF decreased from 13.6% to 11.7% [sRR: 0.76 (0.68–0.84)], and 5-year incidence of subsequent recurrent MI decreased from 23.4% to 17.7% [sRR: 0.65 (0.52–0.78)]. While mortality and subsequent recurrent MI decreased consistently across subgroups, stratified analyses revealed that the 5-year incidence of HHF increased from 23.9% to 26.2% in patients with previous HF and from 14.3% to 15.9% in males aged ≥75 years. Conclusion: Mortality has decreased in parallel with intensified pharmacologic and invasive management of patients with recurrent MI. However, there has been little improvement in heart failure hospitalisations, underscoring that directed preventive strategies are needed to mitigate the heart failure risk in patients with recurrent MI.
- 1 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (12) , 723-731
Long-term outcomes of recurrent myocardial infarction: a nationwide Danish study
Aims: During the past decades outcomes of first-time myocardial infarction (MI) have improved substantially. However, it is unknown if the prognosis following a recurrent MI has also improved similarly. Methods and results: We conducted a nationwide registry-based study including all patients with first-time recurrent MI in Denmark during 2003 to 2022. Cumulative incidences and standardized risk ratios (sRR) of mortality, hospitalisation for heart failure (HHF), and subsequent recurrent MI were reported along with stratified analyses by age, sex, and HF status at baseline. A total of 24,799 patients with recurrent MI were identified. Between 2003 and 2007 (n = 7368) and 2018–2022 (n = 4928), their median age decreased from 75 to 73 years. The prevalence of non-cardiovascular comorbidities increased. The use of lipid-lowering treatment at baseline increased (53.7% to 76.6%), as well as procedures performed in relation to recurrent MI (coronary angiogram, 41.2% to 77.4%; percutaneous coronary intervention, 26.8% to 54.0%). 5-year mortality decreased from 54.1% to 37.3% [sRR: 0.78 (0.74–0.82)], 5-year incidence of HHF decreased from 13.6% to 11.7% [sRR: 0.76 (0.68–0.84)], and 5-year incidence of subsequent recurrent MI decreased from 23.4% to 17.7% [sRR: 0.65 (0.52–0.78)]. While mortality and subsequent recurrent MI decreased consistently across subgroups, stratified analyses revealed that the 5-year incidence of HHF increased from 23.9% to 26.2% in patients with previous HF and from 14.3% to 15.9% in males aged ≥75 years. Conclusion: Mortality has decreased in parallel with intensified pharmacologic and invasive management of patients with recurrent MI. However, there has been little improvement in heart failure hospitalisations, underscoring that directed preventive strategies are needed to mitigate the heart failure risk in patients with recurrent MI.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037973
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
Background: Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results: We identified 131 235 patients with new‐onset HF (median age 74 years, 39.7% women) from Danish nationwide registers in 1999 to 2017. Stratification according to the Hospital Frailty Risk Score resulted in (1) 102 635 (78%) nonfrail, (2) 26 054 (20%) moderately frail, and (3) 2609 (2%) severely frail patients. The proportion of moderately frail patients increased from 13.2% to 24.9%. Five‐year absolute risks of all‐cause mortality, HF hospitalization, and non‐HF hospitalization were calculated using the Kaplan‐Meier and Aalen‐Johansen estimators. From 1999 to 2002 to 2003 to 2017, all‐cause mortality risk (95% CI) declined from 56.4% (55.8%–57.0%) to 33.3% (32.6%–34.1%), 79.8% (78.5%–81.0%) to 58.6% (57.2%–60.1%), and 90.8% (85.6%–96.0%) to 79.8% (76.4%–83.2%) in nonfrail, moderately frail, and severely frail patients, respectively. HF hospitalization risk remained almost constant over the study period. Non‐HF hospitalization risk declined from 74.0% (73.5%–74.5%) to 65.8% (65.0%–66.5%) in nonfrail patients and remained stable overall in moderately frail and severely frail patients over the study period. Conclusions: We observed an increase in frail patients. Mortality decreased for all frailty groups but remained high for severely frail patients. These findings indicate the need for further evidence on the optimization of care for frail patients with HF, and future research should address the development of comprehensive management strategies, integrating frailty assessment into standard clinical care and focused care for older patients with HF.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037973
Open AccessTemporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
Background: Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results: We identified 131 235 patients with new‐onset HF (median age 74 years, 39.7% women) from Danish nationwide registers in 1999 to 2017. Stratification according to the Hospital Frailty Risk Score resulted in (1) 102 635 (78%) nonfrail, (2) 26 054 (20%) moderately frail, and (3) 2609 (2%) severely frail patients. The proportion of moderately frail patients increased from 13.2% to 24.9%. Five‐year absolute risks of all‐cause mortality, HF hospitalization, and non‐HF hospitalization were calculated using the Kaplan‐Meier and Aalen‐Johansen estimators. From 1999 to 2002 to 2003 to 2017, all‐cause mortality risk (95% CI) declined from 56.4% (55.8%–57.0%) to 33.3% (32.6%–34.1%), 79.8% (78.5%–81.0%) to 58.6% (57.2%–60.1%), and 90.8% (85.6%–96.0%) to 79.8% (76.4%–83.2%) in nonfrail, moderately frail, and severely frail patients, respectively. HF hospitalization risk remained almost constant over the study period. Non‐HF hospitalization risk declined from 74.0% (73.5%–74.5%) to 65.8% (65.0%–66.5%) in nonfrail patients and remained stable overall in moderately frail and severely frail patients over the study period. Conclusions: We observed an increase in frail patients. Mortality decreased for all frailty groups but remained high for severely frail patients. These findings indicate the need for further evidence on the optimization of care for frail patients with HF, and future research should address the development of comprehensive management strategies, integrating frailty assessment into standard clinical care and focused care for older patients with HF.
- Open Access
- 5 December 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (23) , e030191
Short‐ and Long‐Term Mortality for Patients With and Without a Cancer Diagnosis Following Pulmonary Embolism in Denmark, 2000 to 2020: A Nationwide Study
Background: New treatment regimens have been introduced in the past 20 years, which may influence the short‐ and long‐term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. However, newer studies investigating these trends are lacking. Therefore, we aimed to investigate the 30‐ and 31‐ to 365‐day mortality following pulmonary embolism. Methods and Results: Using the Danish nationwide registries, patients with a diagnosis of pulmonary embolism between 2000 and 2020 were included. Age‐ and sex‐standardized 30‐ and 31‐ to 365‐day mortality was calculated and stratified by cancer status. In total, 60 614 patients (29.6% with recent cancer; mean age, 68.2 years) were included. The 30‐day mortality for patients with no recent cancer decreased from 19.1% (95% CI, 17.9%–20.4%) in 2000 to 7.3% (95% CI, 6.7%–8.0%) in 2018 to 2020 (hazard ratio [HR], 0.36 [95% CI, 0.32–0.40]; P P P P =0.69). Conclusions: From 2000 to 2020, improvements were observed in 30‐day mortality following pulmonary embolism regardless of cancer status. For patients with recent cancer, 31‐ to 365‐day mortality did not improve, whereas a minor improvement was observed for patients without recent cancer.
- 5 December 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (23) , e030191
Open AccessShort‐ and Long‐Term Mortality for Patients With and Without a Cancer Diagnosis Following Pulmonary Embolism in Denmark, 2000 to 2020: A Nationwide Study
Background: New treatment regimens have been introduced in the past 20 years, which may influence the short‐ and long‐term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. However, newer studies investigating these trends are lacking. Therefore, we aimed to investigate the 30‐ and 31‐ to 365‐day mortality following pulmonary embolism. Methods and Results: Using the Danish nationwide registries, patients with a diagnosis of pulmonary embolism between 2000 and 2020 were included. Age‐ and sex‐standardized 30‐ and 31‐ to 365‐day mortality was calculated and stratified by cancer status. In total, 60 614 patients (29.6% with recent cancer; mean age, 68.2 years) were included. The 30‐day mortality for patients with no recent cancer decreased from 19.1% (95% CI, 17.9%–20.4%) in 2000 to 7.3% (95% CI, 6.7%–8.0%) in 2018 to 2020 (hazard ratio [HR], 0.36 [95% CI, 0.32–0.40]; P P P P =0.69). Conclusions: From 2000 to 2020, improvements were observed in 30‐day mortality following pulmonary embolism regardless of cancer status. For patients with recent cancer, 31‐ to 365‐day mortality did not improve, whereas a minor improvement was observed for patients without recent cancer.
- 1 October 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (10) , e010617
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study
BACKGROUND: Patients with heart failure are vulnerable to the SARS-CoV-2 infection. However, limited evidence exists on the safety of the SARS-CoV-2 mRNA vaccines in this patient population. The objective of this study was to investigate the risk of all-cause mortality, worsening heart failure, venous thromboembolism, and myocarditis associated with the mRNA vaccines in patients with heart failure. METHODS: Using Danish nationwide registries, 2 cohorts were constructed: (1) all prevalent heart failure patients in 2019 aged 40 to 95 years and (2) all prevalent heart failure patients in 2021 aged 40 to 95 years, who were vaccinated with either of the 2 mRNA vaccines (BNT162B2 or mRNA-1273). The patients in the 2 cohorts were matched 1:1 using exact exposure matching on age, sex, and duration of heart failure. To estimate standardized absolute risks, outcome-specific Cox regression analyses were performed. RESULTS: The total study population comprised 101 786 patients. The median age of the study population was 74 years (interquartile range, 66–81). The standardized risk of all-cause mortality within 90 days was 2.23% (95% CI, 2.10%–2.36%) in the vaccinated cohort and 2.56% (95% CI, 2.43%–2.70%) in the unvaccinated cohort (90-day risk difference, −0.33% [95% CI, −0.52% to −0.15%]). The standardized risk of worsening heart failure within 90 days was 1.10% (95% CI, −1.01% to 1.19%) in the 2021 (vaccinated) cohort and 1.08% (95% CI, 0.99%–1.17%) in the 2019 (unvaccinated) cohort (risk difference, 0.02% [95% CI, −0.11% to 0.15%]). No significant differences were found regarding venous thromboembolism or myocarditis. CONCLUSIONS: Receiving an mRNA vaccine was not associated with an increased risk of worsening heart failure, myocarditis, venous thromboembolism, or all-cause mortality.
- 1 October 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (10) , e010617
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study
BACKGROUND: Patients with heart failure are vulnerable to the SARS-CoV-2 infection. However, limited evidence exists on the safety of the SARS-CoV-2 mRNA vaccines in this patient population. The objective of this study was to investigate the risk of all-cause mortality, worsening heart failure, venous thromboembolism, and myocarditis associated with the mRNA vaccines in patients with heart failure. METHODS: Using Danish nationwide registries, 2 cohorts were constructed: (1) all prevalent heart failure patients in 2019 aged 40 to 95 years and (2) all prevalent heart failure patients in 2021 aged 40 to 95 years, who were vaccinated with either of the 2 mRNA vaccines (BNT162B2 or mRNA-1273). The patients in the 2 cohorts were matched 1:1 using exact exposure matching on age, sex, and duration of heart failure. To estimate standardized absolute risks, outcome-specific Cox regression analyses were performed. RESULTS: The total study population comprised 101 786 patients. The median age of the study population was 74 years (interquartile range, 66–81). The standardized risk of all-cause mortality within 90 days was 2.23% (95% CI, 2.10%–2.36%) in the vaccinated cohort and 2.56% (95% CI, 2.43%–2.70%) in the unvaccinated cohort (90-day risk difference, −0.33% [95% CI, −0.52% to −0.15%]). The standardized risk of worsening heart failure within 90 days was 1.10% (95% CI, −1.01% to 1.19%) in the 2021 (vaccinated) cohort and 1.08% (95% CI, 0.99%–1.17%) in the 2019 (unvaccinated) cohort (risk difference, 0.02% [95% CI, −0.11% to 0.15%]). No significant differences were found regarding venous thromboembolism or myocarditis. CONCLUSIONS: Receiving an mRNA vaccine was not associated with an increased risk of worsening heart failure, myocarditis, venous thromboembolism, or all-cause mortality.